Blueprint Medicines (NASDAQ:BPMC) PT Raised to $130.00 at Stifel Nicolaus

Blueprint Medicines (NASDAQ:BPMC) had its target price raised by investment analysts at Stifel Nicolaus from $120.00 to $130.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 38.24% from the company’s current price.

A number of other research firms have also commented on BPMC. Wedbush restated an “outperform” rating and issued a $110.00 price target on shares of Blueprint Medicines in a research report on Friday. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $114.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Barclays increased their target price on Blueprint Medicines from $58.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 13th. Finally, Citigroup lifted their price target on Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a report on Friday, February 16th. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Hold” and an average target price of $91.57.

Blueprint Medicines Price Performance

Shares of BPMC traded up $3.31 during mid-day trading on Friday, reaching $94.04. The company had a trading volume of 218,278 shares, compared to its average volume of 757,465. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. The company has a market capitalization of $5.76 billion, a P/E ratio of -11.11 and a beta of 0.63. Blueprint Medicines has a twelve month low of $43.89 and a twelve month high of $101.00. The company’s 50-day moving average is $90.73 and its 200-day moving average is $78.51.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The firm had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same period in the prior year, the company posted ($2.65) earnings per share. The business’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, equities analysts anticipate that Blueprint Medicines will post -5.41 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In related news, insider Christopher K. Murray sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. Following the sale, the insider now owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Christopher K. Murray sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. Following the completion of the sale, the insider now directly owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the completion of the transaction, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,289 shares of company stock valued at $8,314,163. Corporate insiders own 3.88% of the company’s stock.

Institutional Trading of Blueprint Medicines

A number of institutional investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Blueprint Medicines by 8.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 36,929 shares of the biotechnology company’s stock valued at $3,503,000 after purchasing an additional 2,884 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Blueprint Medicines in the 1st quarter valued at $218,000. Diversified Trust Co lifted its position in Blueprint Medicines by 3.6% during the 1st quarter. Diversified Trust Co now owns 14,472 shares of the biotechnology company’s stock worth $1,373,000 after buying an additional 498 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Blueprint Medicines during the 4th quarter worth about $9,768,000. Finally, Vanguard Group Inc. boosted its stake in shares of Blueprint Medicines by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after buying an additional 147,827 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.